Application of interim 18FFDG PET-CT in lymphoma

doi:10.3760/cma.j.issn.1673-422X.2015.06.020

Abstract

Abstract: Interim fluorine 18 fluorodeoxyglucose (^18FFDG) positron emission tomography (PET) integrated with computed tomography (CT) provides both metabolic and morphologic information, which becomes one of the most sensitive tools to evaluate the efficacy of the therapy and predict the prognosis of patients with lymphoma. Meanwhile, it is the basis for guiding trial design and changing clinical practice. However, it is still a controversial issue in the ideal utilization of interim ^18FFDG PET-CT imaging for the patients with lymphoma.

Key words: Positron emission tomography, Lymphoma, Prognosis, Metaphase

Zhang Yuewei, Wang Xuejuan, Yang Zhi, Zhu Jun. Application of interim ^18FFDG PET-CT in lymphoma[J]. Journal of International Oncology, 2015, 42(6): 472-474.

References

［1］ Itti E, Meignan M, BerrioloRiedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large Bcell lymphoma: comparison between Deauville criteria and ΔSUVmax［J］. Eur J Nucl Med Mol Imaging, 2013, 40(9): 1312-1320. ［2］ Dupuis J, BerrioloRiedinger A, Julian A, et al. Impact of ［(18)F］fluorodeoxyglucose positron emission tomography response evaluation in patients with hightumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d′Etudes des Lymphomes de l′Adulte and GOELAMS［J］. J Clin Oncol, 2012, 30(35): 4317-4322. ［3］ Casasnovas RO, Meignan M, BerrioloRiedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B cell lymphoma［J］. Blood, 2011, 118(1): 37-43. ［4］ Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group［J］. J Clin Oncol, 2014, 32(27): 3048-3058. ［5］ Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in Oncology［J］. Cancers (Basel), 2014, 6(4): 1821-1889. ［6］ Kostakoglu L, Cheson BD. Stateoftheart research on "lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response"［J］. Front Oncol, 2013, 3: 212. ［7］ Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin′s disease［J］. Haematologica, 2006, 91(4): 475-481. ［8］ Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18FFDG-PET in Hodgkin′s lymphoma: evaluation on 304 patients［J］. Eur J Nucl Med Mol Imaging, 2012, 39(1): 4-12. ［9］ Iltis A, Eder V, Blasco H, et al. Decisional early interim FFluoro2DeoxyDGlucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma［J］. Acta Haematol, 2015, 133(2): 172-178. ［10］ Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advancedstage Hodgkin lymphoma patients with a interimPET positive after two ABVD courses［J］. Br J Haematol, 2011, 152(5): 551-560. ［11］ Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomographynegative stage Ⅰ/Ⅱ Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial［J］. J Clin Oncol, 2014, 32(12): 1188-1194. ［12］ Lin C, Itti E, Haioun C, et al. Early 18F FDG-PET for prediction of prognosis in patients with diffuse large Bcell lymphoma: SUVbased assessment versus visual analysis［J］. J Nucl Med, 2007, 48(10): 1626-1632. ［13］ Kim J, Hong J, Kim SG, et al. Prognostic value of metabolic tumor volume estimated by (18) F FDG positron emission tomography/computed tomography in patients with diffuse large B cell lymphoma of stage Ⅱ or Ⅲ disease［J］. Nucl Med Mol Imaging, 2014, 48(3): 187-195. ［14］ Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma［J］. Cancer, 2013, 119(6): 1195-1202. ［15］ TychyjPinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study［J］. Eur J Nucl Med Mol Imaging, 2014, 41(3): 408-415. ［16］ Pellegrini C, Argnani L, Broccoli A, et al. Prognostic value of interim positron emission tomography in patients with peripheral T cell lymphoma［J］. Oncologist, 2014, 19(7): 746-750. ［17］ Li YJ, Li ZM, Xia XY, et al. Prognostic value of interim and post therapy 18FFDG-PET/CT in patients with mature T cell and natural killer cell lymphomas［J］. J Nucl Med, 2013, 54(4): 507-515. ［18］ González Barca E, Canales M, Cortés M, et al. Predictive value of interim 18F FDG-PET/CT for eventfree survival in patients with diffuse large B cell lymphoma homogenously treated in a phase Ⅱ trial with six cycles of R-CHOP 14 plus pegfilgrastim as first line treatment［J］. Nucl Med Commun, 2013, 34(10): 946-952.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.

Application of interim ^18FFDG PET-CT in lymphoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments